{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T09:57:13Z","timestamp":1785491833041,"version":"3.56.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,12,10]],"date-time":"2020-12-10T00:00:00Z","timestamp":1607558400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,12,10]],"date-time":"2020-12-10T00:00:00Z","timestamp":1607558400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1038\/s41440-020-00589-8","type":"journal-article","created":{"date-parts":[[2020,12,10]],"date-time":"2020-12-10T03:04:18Z","timestamp":1607569458000},"page":"426-434","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Long-term impact of spironolactone compliance on microalbuminuria in patients with primary aldosteronism"],"prefix":"10.1038","volume":"44","author":[{"given":"Xiaotong","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menghui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junli","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoliang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanfang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,12,10]]},"reference":[{"key":"589_CR1","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/bs.vh.2018.10.006","volume":"109","author":"JW Funder","year":"2019","unstructured":"Funder JW. Primary aldosteronism: present and future. Vitam Horm 2019;109:285\u2013302.","journal-title":"Vitam Horm"},{"key":"589_CR2","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1210\/jc.2015-4061","volume":"101","author":"JW Funder","year":"2016","unstructured":"Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2016;101:1889\u2013916.","journal-title":"J Clin Endocrinol Metab"},{"key":"589_CR3","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1016\/j.jacc.2017.01.052","volume":"69","author":"S Monticone","year":"2017","unstructured":"Monticone S, Burrello J, Tizzani D, Bertello C, Viola A, Buffolo F, et al. Prevalence and clinical manifestations of primary aldosteronism encountered in primary care practice. J Am Coll Cardiol 2017;69:1811\u201320.","journal-title":"J Am Coll Cardiol"},{"key":"589_CR4","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S2213-8587(17)30319-4","volume":"6","author":"S Monticone","year":"2018","unstructured":"Monticone S, D\u2019Ascenzo F, Moretti C, Williams TA, Veglio F, Gaita F, et al. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 2018;6:41\u201350.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"589_CR5","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1093\/eurheartj\/ehq254","volume":"32","author":"T Thum","year":"2011","unstructured":"Thum T, Schmitter K, Fleissner F, Wiebking V, Dietrich B, Widder JD, et al. Impairment of endothelial progenitor cell function and vascularization capacity by aldosterone in mice and humans. Eur Heart J 2011;32:1275\u201386.","journal-title":"Eur Heart J"},{"key":"589_CR6","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1161\/01.HYP.0000226054.53527.bb","volume":"48","author":"D Nagata","year":"2006","unstructured":"Nagata D, Takahashi M, Sawai K, Tagami T, Usui T, Shimatsu A, et al. Molecular mechanism of the inhibitory effect of aldosterone on endothelial NO synthase activity. Hypertension 2006;48:165\u201371.","journal-title":"Hypertension"},{"key":"589_CR7","doi-asserted-by":"publisher","first-page":"e906","DOI":"10.1161\/CIRCULATIONAHA.111.078824","volume":"124","author":"JA Vita","year":"2011","unstructured":"Vita JA. Endothelial function. Circulation 2011;124:e906\u201312.","journal-title":"Circulation"},{"key":"589_CR8","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1038\/jhh.2014.11","volume":"28","author":"G Liu","year":"2014","unstructured":"Liu G, Yin GS, Tang JY, Ma DJ, Ru J, Huang XH. Endothelial dysfunction in patients with primary aldosteronism: a biomarker of target organ damage. J Hum Hypertens 2014;28:711\u20135.","journal-title":"J Hum Hypertens"},{"key":"589_CR9","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/BF00285287","volume":"32","author":"T Deckert BF-R","year":"1989","unstructured":"Deckert BF-R T, Borch-Johnsen K, et al. Albuminuria reflects widespread vascular damage. Diabetologia 1989;32:219\u201326.","journal-title":"Diabetologia"},{"key":"589_CR10","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1161\/01.HYP.0000230444.01215.6a","volume":"48","author":"GP Rossi","year":"2006","unstructured":"Rossi GP, Bernini G, Desideri G, Fabris B, Ferri C, Giacchetti G, et al. Renal damage in primary aldosteronism: results of the PAPY Study. Hypertension 2006;48:232\u20138.","journal-title":"Hypertension"},{"key":"589_CR11","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1681\/ASN.2005121288","volume":"17","author":"CD Stehouwer","year":"2006","unstructured":"Stehouwer CD, Smulders YM. Microalbuminuria and risk for cardiovascular disease: analysis of potential mechanisms. J Am Soc Nephrol 2006;17:2106\u201311.","journal-title":"J Am Soc Nephrol"},{"key":"589_CR12","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1586\/14737159.7.6.793","volume":"7","author":"AMATJ Wang","year":"2007","unstructured":"Wang AMATJ. Evaluating the role of biomarkers for cardiovascular risk prediction: focus on CRP, BNP and urinary microalbumin. Expert Rev Mol Diagn 2007;7:793\u2013804.","journal-title":"Expert Rev Mol Diagn"},{"key":"589_CR13","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/hr.2015.129","volume":"39","author":"S Karashima","year":"2016","unstructured":"Karashima S, Yoneda T, Kometani M, Ohe M, Mori S, Sawamura T, et al. Comparison of eplerenone and spironolactone for the treatment of primary aldosteronism. Hypertens Res 2016;39:133\u20137.","journal-title":"Hypertens Res"},{"key":"589_CR14","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1530\/EJE-12-0631","volume":"168","author":"V Fourkiotis","year":"2013","unstructured":"Fourkiotis V, Vonend O, Diederich S, Fischer E, Lang K, Endres S, et al. Effectiveness of eplerenone or spironolactone treatment in preserving renal function in primary aldosteronism. Eur J Endocrinol 2013;168:75\u201381.","journal-title":"Eur J Endocrinol"},{"key":"589_CR15","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1210\/jc.2013-2180","volume":"99","author":"Y Iwakura","year":"2014","unstructured":"Iwakura Y, Morimoto R, Kudo M, Ono Y, Takase K, Seiji K, et al. Predictors of decreasing glomerular filtration rate and prevalence of chronic kidney disease after treatment of primary aldosteronism: renal outcome of 213 cases. J Clin Endocrinol Metab 2014;99:1593\u20138.","journal-title":"J Clin Endocrinol Metab"},{"key":"589_CR16","doi-asserted-by":"publisher","first-page":"e184","DOI":"10.1111\/j.1464-5491.2012.03585.x","volume":"29","author":"SE Nielsen","year":"2012","unstructured":"Nielsen SE, Persson F, Frandsen E, Sugaya T, Hess G, Zdunek D, et al. Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo-controlled crossover study. Diabet Med 2012;29:e184\u2013190.","journal-title":"Diabet Med"},{"key":"589_CR17","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.jdiacomp.2007.05.003","volume":"22","author":"A Jawa","year":"2008","unstructured":"Jawa A, Nachimuthu S, Pendergrass M, Asnani S, Fonseca V. Beta-blockers have a beneficial effect upon endothelial function and microalbuminuria in African-American subjects with diabetes and hypertension. J Diabetes Complications 2008;22:303\u20138.","journal-title":"J Diabetes Complications"},{"key":"589_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/ijcp.12987","volume":"71","author":"YC Hwang","year":"2017","unstructured":"Hwang YC, Yoon KH, Cha BS, et al. Reduction in microalbuminuria by calcium channel blockers in patients with type 2 diabetes mellitus and hypertension-A randomized, open-label, active-controlled, superiority, parallel-group clinical trial. Int J Clin Pract 2017;71:1\u20138.","journal-title":"Int J Clin Pract"},{"key":"589_CR19","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/jhh.2015.21","volume":"30","author":"Q Luo","year":"2016","unstructured":"Luo Q, Li NF, Yao XG, Zhang DL, Abulikemu SF, Chang GJ, et al. Potential effects of age on screening for primary aldosteronism. J Hum Hypertens 2016;30:53\u201361.","journal-title":"J Hum Hypertens"},{"key":"589_CR20","doi-asserted-by":"publisher","unstructured":"Luo Q, Li N, Wang M, Yao X, Heizhati M, Zhang D, et al. Mild primary aldosteronism (PA) followed by overt PA are possibly the most common forms of low renin hypertension: a single-center retrospective study. J Hum Hypertens 2019; https:\/\/doi.org\/10.1038\/s41371-019-0291-y.","DOI":"10.1038\/s41371-019-0291-y"},{"key":"589_CR21","doi-asserted-by":"publisher","unstructured":"Tuersun T, Luo Q, Zhang Z, Wang G, Zhang D, Wang M, et al. Abdominal aortic calcification is more severe in unilateral primary aldosteronism patients and is associated with elevated aldosterone and parathyroid hormone levels. Hypertens Res 2020; https:\/\/doi.org\/10.1038\/s41440-020-0529-7.","DOI":"10.1038\/s41440-020-0529-7"},{"key":"589_CR22","unstructured":"Chinese Hypertension League CSoC, Hypertension Committee of the Chinese Medical Doctor Association,et al. 2018 Chinese Guidelines for Prevention and Treatment of Hypertension-A report of the Revision Committee of Chinese Guidelines for Prevention and Treatment of Hypertension. J Geriatr Cardiol. 2018;16:182\u2013241."},{"key":"589_CR23","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s00268-017-4311-1","volume":"42","author":"BS Miller","year":"2018","unstructured":"Miller BS, Turcu AF, Nanba AT, Hughes DT, Cohen MS, Gauger PG, et al. Refining the definitions of biochemical and clinical cure for primary aldosteronism using the primary aldosteronism surgical outcome (PASO) classification system. World J Surg 2018;42:453\u201363.","journal-title":"World J Surg"},{"key":"589_CR24","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s00392-010-0194-y","volume":"99","author":"C Ukena","year":"2010","unstructured":"Ukena C, Mahfoud F, Kindermann M, Graber S, Kindermann I, Schneider M, et al. Smoking is associated with a high prevalence of microalbuminuria in hypertensive high-risk patients: data from I-SEARCH. Clin Res Cardiol 2010;99:825\u201332.","journal-title":"Clin Res Cardiol"},{"key":"589_CR25","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1177\/0003319713513144","volume":"66","author":"G Hao","year":"2013","unstructured":"Hao G, Wang Z, Zhang L, Chen Z, Wang X, Guo M, et al. Prevalence of microalbuminuria among middle-aged population of China. Angiology 2013;66:49\u201356.","journal-title":"Angiology"},{"key":"589_CR26","doi-asserted-by":"publisher","first-page":"2510","DOI":"10.1097\/HJH.0000000000001476","volume":"35","author":"C Catena","year":"2017","unstructured":"Catena C, Colussi G, Martinis F, Novello M, Sechi LA. Microalbuminuria and plasma aldosterone levels in nondiabetic treatment-naive patients with hypertension. J Hypertens 2017;35:2510\u20136.","journal-title":"J Hypertens"},{"key":"589_CR27","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/s41371-017-0013-2","volume":"32","author":"PM da Costa","year":"2018","unstructured":"da Costa PM, Cortez AF, de Souza F, Mares GS, Dos Santos BDM, Muxfeldt ES. Prognostic impact of baseline urinary albumin excretion rate in patients with resistant hypertension: a prospective cohort study. J Hum Hypertens 2018;32:139\u201349.","journal-title":"J Hum Hypertens"},{"key":"589_CR28","first-page":"1","volume":"10","author":"H Ota","year":"2015","unstructured":"Ota H, Takehara N, Aonuma T, et al. Association between microalbuminuria predicting in-stent restenosis after myocardial infarction and cellular senescence of endothelial progenitor cells. PLoS ONE 2015;10:1\u201313.","journal-title":"PLoS ONE"},{"key":"589_CR29","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1161\/01.HYP.0000154082.72286.2a","volume":"45","author":"H Ibsen","year":"2005","unstructured":"Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm LH, Mogensen CE, et al. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension 2005;45:198\u2013202.","journal-title":"Hypertension"},{"key":"589_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1161\/CIRCHEARTFAILURE.118.005288","volume":"11","author":"S Selvaraj","year":"2018","unstructured":"Selvaraj S, Claggett B, Shah SJ, et al. Prognostic value of albuminuria and influence of spironolactone in heart failure with preserved ejection fraction. Circ Heart Fail 2018;11:1\u201310.","journal-title":"Circ Heart Fail"},{"key":"589_CR31","unstructured":"Chinese Society of Endocrinology Adrenal Group.Expert consensus on the diagnosis and treatment of primary aldosteronism.Chin J Endocrinol Metab, 2016;32:188\u201395."},{"key":"589_CR32","doi-asserted-by":"publisher","unstructured":"Satoh M, Maruhashi T, Yoshida Y, Shibata H Systematic review of the clinical outcomes of mineralocorticoid receptor antagonist treatment versus adrenalectomy in patients with primary aldosteronism. Hypertens Res. 2019; https:\/\/doi.org\/10.1038\/s41440-019-0244-4.","DOI":"10.1038\/s41440-019-0244-4"},{"key":"589_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1470320316652047","volume":"17","author":"F Persson","year":"2016","unstructured":"Persson F, Lindhardt M, Rossing P, et al. Prevention of microalbuminuria using early intervention with renin-angiotensin system inhibitors in patients with type 2 diabetes: a systematic review. J Renin Angiotensin Aldosterone Syst 2016;17:1\u201310.","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"589_CR34","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.amjms.2018.01.017","volume":"355","author":"Y Chen","year":"2018","unstructured":"Chen Y, Liu P, Chen X, Li Y, Zhang F, Wang Y. Effects of different doses of irbesartan combined with spironolactone on urinary albumin excretion rate in elderly patients with early type 2 diabetic nephropathy. Am J Med Sci 2018;355:418\u201324.","journal-title":"Am J Med Sci"},{"key":"589_CR35","doi-asserted-by":"publisher","first-page":"R147","DOI":"10.1530\/EJE-19-0215","volume":"181","author":"B Lechner","year":"2019","unstructured":"Lechner B, Lechner K, Heinrich D, Adolf C, Holler F, Schneider H, et al. Therapy of endocrine disease: medical treatment of primary aldosteronism. Eur J Endocrinol 2019;181:R147\u201353.","journal-title":"Eur J Endocrinol"},{"key":"589_CR36","first-page":"768","volume":"3","author":"LHundemerM,MPH Gregory","year":"2018","unstructured":"Gregory LHundemerM,MPH, Gary CCurhan,MD,SCD, Nicholas Yozamp,MD, et al. Incidence of atrial fibrillation and mineralocorticoid receptor activity in patients with medically and surgically treated primary aldosteronism. JAMACardiology 2018;3:768\u201374.","journal-title":"JAMACardiology"},{"key":"589_CR37","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/0002-9149(87)91030-7","volume":"60","author":"Jeunemaitre X","year":"1987","unstructured":"X Jeunemaitre, G Chatellier, C Kreft-Jais, A Charru, C DeVries, PF Plouin. et al. Efficacy and tolerance of spironolactone in essential hypertension. Am J Cardiol. 1987;60:820\u20135.","journal-title":"Am J Cardiol"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41440-020-00589-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41440-020-00589-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41440-020-00589-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:23:13Z","timestamp":1684617793000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41440-020-00589-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,10]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["589"],"URL":"https:\/\/doi.org\/10.1038\/s41440-020-00589-8","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,10]]},"assertion":[{"value":"27 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}